Ionis Pharmaceuticals Inc
(NAS:IONS)
$
35.91
-0.42 (-1.16%)
Market Cap: 5.74 Bil
Enterprise Value: 4.73 Bil
PE Ratio: 0
PB Ratio: 8.65
GF Score: 40/100 Ionis Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022 / 03:00PM GMT
Release Date Price:
$35.88
(-2.15%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks very much, everybody, for continuing on. It's my pleasure to be hosting Eric Swayze, Executive Vice President of Research at Ionis; and Holly Kordasiewicz, who runs their neurology research group. We have a lot of stuff to get into, a lot of programs. We can talk maybe a little bit about today's data release as well and any implications.
Questions & Answers
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
But do you want to maybe just kick it off, either Eric or Holly, and just talk a bit about your neuro pipeline right now and where the different programs stand?
Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research
Yes. I'd love to do that, and thanks for having us on, Paul. I think that a little overview of our neuro portfolio strategy and depth is
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot